Back to News
Market Impact: 0.18
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy
Source: zacks.com
Analyst InsightsCompany FundamentalsInvestor Sentiment & Positioning
Actuate Therapeutics (ACTU) was upgraded to a Zacks Rank #2 (Buy), citing growing optimism around its earnings outlook. The note suggests upside momentum for the stock in the near term, but does not provide new financial figures or guidance changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.22
Ticker Sentiment
ACTU0.35
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Palantir patient data tech rejected by many NHS trusts in England
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- Wall Street Anxiety Spreads as AI Rout Meets $110 Oil Shock
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'